After participating in this educational activity, the participant should be better able to: 1. Describe the current use of sedation in mechanically ventilated patients. 2. Explain the relationship between sedation use and the length of mechanical ventilation. 3. Use this information in a clinical setting.
P atients in intensive care frequently require invasive monitoring and support that can lead to anxiety, agitation, and pain (1, 2) . Use of intravenous (IV) sedatives is considered integral to the care of these patients, especially for those requiring invasive mechanical ventilation (3, 4) . There are multiple options when choosing a sedative to use in the intensive care unit (ICU). Recent U.S. guidelines for sedation cite lorazepam as the sedative of choice for use on most ICU patients (4) , and Italian guidelines state that benzodiazepines are the most commonly used drugs to sedate mechanically ventilated patients (5) .
Existing studies that try to quantify sedation practice frequently rely on survey methodology to gain an understanding at either the national or international level (6, 7, 8, 9) . But surveys are poorly equipped to address this issue, because actual practice frequently differs dramatically from stated practice (10) . The majority of studies on choice of sedative infusion are clinical trials that compare the efficacy of a benzodiazepine to propofol (3, 11, 12, 13) . Recent interest has centered on dexmedetomidine, a selective alpha-2 agonist with sedative and anxiolytic properties, with comparison primarily to benzodiazepines on the assumption that benzodiazepines represent the standard of care for patients requiring mechanical ventilation for more than short periods of time (14, 15) . The idea that benzodiazepines are the standard of care is reinforced by older guidelines that recommended propofol only for short-term sedation (4, 16) . One survey has also shown that, at least in Great Britain, clinicians perceived a preference for benzodiazepines over propofol for "long-term" sedation (8) .
The purpose of this study was to examine the actual IV infusion sedation practice in mechanically ventilated patients in the ICU in the United States. We used a large, multicentered database that captures detailed clinical and demographic data as well as IV infusion medications given during the stay of mechanically ventilated patients in intensive care. We describe the characteristics of patients receiving IV infusion sedation, the relationship between duration of mechanical ventilation and IV infusion sedation use, and trends in use over time.
METHODS

Study Design
We performed a retrospective cohort study of IV infusion sedation in patients in the Project IMPACT database (Cerner Corp., Kansas City, MO), which provides regular performance audits and feedback to participating ICUs. Participation is voluntary and hospitals and ICUs pay for the service. Data are collected at each institution by on-site data collectors who are certified in advance by Project IMPACT to assure standardization and uniformity in data definitions and entry (17) . Hospitals participating in Project IMPACT tend to be larger and more urban than the general population hospitals, but are diverse in size and location.
Patients and Variables
We included patients from years 2001 through 2007. Data were either from consecutive admissions to each intensive care unit, or a random sample of admissions. The latter sites collected information on 50% or 75% of all patients; the percentage was determined quarterly before data collection commenced and random sampling then proceeded accordingly. We excluded patients from a single military hospital and coronary care units. We also excluded readmissions to intensive care during the same hospitalization, patients Ͻ18 yrs old, and patients missing information on age, gender, hospital mortality, or length of stay. We examined data on all patients who received mechanical ventilation.
Data were available on all IV infusions of medications given in the ICU. Complete data were not available on medications administered in other ways, such as bolus sedation doses, so we examined only IV infusion sedatives. Overall, 1835 patients (1.7%) had no information on IV infusion medications. We assumed these patients had not received any IV infusion sedation. We grouped patients as receiving any IV infusion sedation, defined as midazolam or lorazepam, propofol, or dexmedetomidine at any time during their ICU admission. Diazepam was not included because it is not usually administered as a continuous infusion, and is not included as a possible infusion in the 2002 Society of Critical Care Medicine guidelines on sedation (4) . In addition to examining patients by individual sedative used, we also grouped patients as receiving propofol only or benzodiazepines only. A smaller proportion (2.6%) of patients received a combination of propofol and benzodiazepines; we did not examine this group in any further detail.
Analysis
First, we compared the patient characteristics of mechanically ventilated patients who did or did not receive any IV infusion sedation while in the ICU. We then compared the demographics, clinical characteristics, and outcomes of patients who received either propofol only or benzodiazepines only. We examined differences between sedative groups using the chi-square test, a Student's t test, or a nonparametric test (the Kruskal-Wallis test) as appropriate. We used multivariable logistic re- gression to assess factors independently associated with receiving IV infusion sedation. Variables for the model were selected a priori based on the literature (18) We examined whether IV sedation choices changed based on the duration of mechanical ventilation. For this analysis, we used data from the first recorded episode of mechanical ventilation. Type of IV infusion sedation was examined by calculating the percentage of patients on each day of mechanical ventilation who received propofol, a benzodiazepine, or dexmedetomidine. We also quantified the total duration of infusion of each sedative, as well as the ratio of duration of sedation to duration of mechanical ventilation to assess what percentage of time on the ventilator patients received each sedative. Next, we examined variation in sedation strategy by hospital and ICU characteristics, looking at both the frequency of overall IV infusion sedative use and the specific choice of IV infusion sedative. We compared sedation use between hospitals based on location (urban, suburban, and rural, as assigned by the Center for Medicare/Medicaid), and hospital type (academic, community forprofit, community not-for-profit, and Veterans' Administration). We grouped ICUs by type (mixed medical-surgical, medical, surgical, neurological, and cardio-thoracic). We designated burn and trauma ICUs as surgical. Chisquare tests were used to compare sedation use between groups.
We also examined trends in the use of IV infusion sedation over time, looking at both sedation in general and specific sedative agents.
We used year as the independent variable, and receipt of sedation (or a specific sedative agent) as the dependent variable. To examine the statistical significance of the time trends we used linear regression with generalized estimating equations to account for the clustering of data by ICUs and variation in participating ICUs over the 7 yrs. We also generated a model that included MPM 0 -III as an additional independent variable (19) to assess whether changes over time could be explained by changes in the severity of illness of patients.
Finally, we assessed the use of IV infusions of narcotics (fentanyl, morphine, or hydromorphone) alone and in patients who received IV infusion sedation. Infusions of alfentanil, sufentanil, and remifentanil were used too infrequently to examine separately (n ϭ 13), but were included in the "any narcotics" group. Database management and statistical analysis were performed using Excel (Microsoft, Redmond, WA), SAS 9.1.3 (SAS Institute, Carey, NC), and Stata 10.0 (StataCorp LP, College Station, TX). This study involved secondary analysis of de-identified data and was deemed exempt from human subjects review by the Columbia Presbyterian Medical Center Institutional Review Board.
RESULTS
Patient Determinants of Receiving IV Infusion Sedation
After exclusions, there were 109,671 patients who received mechanical ventilation (36.9% of all ICU patients; see Fig.  1 ). Of mechanically ventilated patients, 56,443 (51.5%, 95% confidence interval [CI] 51.2-51.8) received some type of IV infusion sedation (Table 1) . Among patients who received IV infusion sedation at any time, propofol was used in 82.2% (95% CI 81.9 -82.5) of cases, a benzodiazepine was used in 31.1% (30.7-31.5), and dexmedetomidine was used in 4.0% (3.8 -4.2). Patients receiving IV infusion sedation were younger (57.1 yrs for those who received sedation vs. 63.2 for those who did not, p Ͻ .001), were more likely to be a medical patient rather than a surgical patient (60.7% vs. 53.4%, p Ͻ .001), and were ventilated for a longer period of time (median 2.4 days, interquartile range [IQR] 0.8 -7.0 vs. 0.8, IQR 0.3-2.5, p Ͻ .001). Patients who received IV infusion sedation had a lower calculated MPM 0 -III probability of mortality (mean 19.5% vs. 26.8%, p Ͻ .001) and were less likely to receive cardiopulmonary resuscitation in the 24 hrs before admission (5.5% vs. 9.2%, p Ͻ .001). Both ICU and hospital length of stay were much longer for patients who received IV infusion sedation, and hospital mortality was lower (22.0% vs. 28.2%, p Ͻ .001).
Among patients who received IV infusion sedation, 66.2% (65.8 -66.6) received only propofol and 16.2% (15.9 -16.5) only benzodiazepines ( Table 2 ). The mean age was similar in the groups that received propofol alone or a benzodiazepine alone. The mean MPM 0 -III mortality probability was also similar in the two groups. Both mean ICU length of stay and mean hospital length of stay were shorter in the propofol group and longer in the benzodiazepine group. Hospital mortality was lower in the propofol alone group (18.8%, vs. 33.0% in the benzodiazepine alone group).
In multivariable modeling, all factors except race were statistically and independently associated with receiving an IV infusion sedative while mechanically ventilated ( Table 3 ). The multivariable model showed that women were less likely to receive IV infusion sedation (odds ratio [OR] 0.80, p Ͻ .001). Age and severity of illness were both inversely associated with the likelihood of receiving IV infusion sedation during mechanical ventilation. Other factors associated with a decreased probability were cardiopulmonary resuscitation within 24 hrs before admission, and having one or more chronic comorbidities. Total length of mechanical ventilation increased likelihood of IV infusion sedation.
Duration of Sedation Administration
The mean total length of propofol use was 2.8 days Ϯ 3.9, shorter than for either of the benzodiazepines (4.2 Ϯ 5.7 for midazolam, and 4.5 Ϯ 5.4 for lorazepam). As a percentage of all time mechanically ventilated, those who received propofol received it for 77.1% Ϯ 47.4% of the time that they were ventilated, for midazolam a p values listed are for comparison of propofol only group to benzodiazepine only group; b for race, n ϭ 53,162 (1.9% missing data). For MPM 0 -III calculations, n ϭ 46,029 (15.1% missing). The MPM 0 -III score is not calculated on patients missing one or more required variables, or on patients with burns, those who had an acute myocardial infarction, or postcardiac surgery. 80.1% Ϯ 54.6%, and for lorazepam 74.1% Ϯ 69.2%. The sedative(s) used on each day of mechanical ventilation are shown in Figure 2 . Up until day 11 of mechanical ventilation, more patients received propofol on any given day compared with benzodiazepines. No more than 20% of mechanically ventilated patients received an IV infusion of benzodiazepines on any given day, even among patients mechanically ventilated for greater than 96 hrs. These findings were consistent for both medical and surgical patient subgroups.
Hospital and ICU Determinants of Intravenous Infusion Sedation
A greater proportion of mechanically ventilated patients in rural hospitals received IV infusion sedation with propofol compared with urban or suburban hospitals, and all three types of hospitals used benzodiazepines for a similar percentage of intensive care patients (Fig. 3a ). There was more variation in use when hospitals were examined by the type of hospital (government, community for-profit, community nonprofit, or academic). Government (Veterans' Administration) hospitals used more IV infusions of benzodiazepines than propofol. Academic hospitals had an overall greater use of IV infusion sedation among mechanically ventilated patients, with a high use of both propofol and benzodiazepines (Fig. 3b) .
The majority of mechanically ventilated patients in Project IMPACT were cared for in mixed medical-surgical intensive care units (n ϭ 65,961) or standalone surgical intensive care units (n ϭ 27,364). Propofol was used in more patients than benzodiazepines across all types of ICUs (Fig. 3c ). Patients in cardiothoracic surgery ICUs and neurological ICUs were least likely to receive a benzodiazepine infusion. . This increase over time was statistically significant, even after accounting for the variation in individual ICUs (p Ͻ .001) and the severity of illness (p Ͻ .001). Broken down by type of IV infusion sedation (Fig. 4) , the majority of the increase in sedation appeared to be Race was included in the model, despite the fact that it was not associated with receiving IV infusion sedation in univariable analysis; b the odds ratio for each 5-yr increase in age. The observed number of patients receiving any sedation was 47,738 while 47,506 patients were predicted to be sedated (ratio ϭ 1.005, p Ͼ .10). Calibration as measured by the Hosmer-Lemeshow statistic was 12.8 (p ϭ .12) and by the Brier statistic was 0.19. Both measures suggest that the model calibrated well. The area under the receiver operating characteristic curve was 0.78, indicating moderately good discrimination; c the odds ratio for each 10% increase in MPM 0 -III probability.
Intravenous Infusion Sedation Over Time
due to an increase in the use of propofol, almost doubling from 31.5% (30.6 -32.4) of mechanically ventilated patients in 2001 to 54.6% (53.6 -55.6) in 2007 (p Ͻ .001). The overall use of both benzodiazepines and dexmedetomidine went up as well (p Ͻ .001). The increase in benzodiazepine use was solely due to an increase in the use of midazolam infusions (p Ͻ .001) rather than lorazepam (p ϭ .58).
Use of Narcotic Infusions
Only 9.9% (9.7-10.2) of patients received a narcotic infusion (fentanyl, morphine, or hydromorphone) in the absence of a sedative infusion (Table 4 ). Of patients who received IV infusion sedation, 38.2% (37.8 -38.6) also received a narcotic infusion. Fentanyl (27.1%, 26.7-27.4) was used more frequently than morphine (12.9%, 12.6 -13.2, p Ͻ .001). Two thirds of patients who received only a benzodiazepine infusion also received a narcotic infusion, vs. a quarter of those receiving only propofol. through 2007, mostly due to an increase in propofol use. Overall, propofol infusions were used much more frequently than benzodiazepines, and were associated with much lower overall use of IV infusion narcotics. The higher use of propofol was apparent in all types of ICUs and hospitals, except for government hospitals. The higher use of propofol was also apparent for patients mechanically ventilated beyond 96 hrs. These results suggest that propofol is the preferred IV infusion sedation agent in most U.S. ICUs and is gaining in popularity compared with other sedatives. Clinical practice guidelines from the Society of Critical Care Medicine leave room for clinician discretion regarding sedation choices. Midazolam is recommended only for short-term use, and lorazepam is recommended for the sedation of most patients, but propofol is the "preferred sedative when rapid awakening…is important" (4) . Data sug-gest that even with clear guidelines, clinicians do not always adhere to the recommendations (20) . A number of surveys have reported on practice in European and Canadian intensive care units (7, 8, 9, 21, 22) . One survey of 647 intensive care physicians in 16 western European countries found substantial variation in selfreported use of sedatives, with midazolam preferred over propofol in France, Germany, the Netherlands, Norway, and Austria (9) , and a recent survey in the United States found high reported use of both propofol and benzodiazepines (21) . However, perception can often differ from reality of practice (10, 23) , and only a few studies have quantified actual sedation practices. The high use of benzodiazepines in France was confirmed with a prospective study that examined sedation of critically ill patients and found that the majority of them received midazolam (24) . An international study of mechanically ventilated patients also found a higher use of benzodiazepine infusions in comparison with propofol (25) . Studies assessing national sedation patterns in the United States have been lacking, likely due to the difficulty of prospectively collecting information on medications in large numbers of patients, or identifying high quality databases that already include this information. Project IMPACT is unique in collecting this level of detail on such a large sample of U.S. intensive care patients.
DISCUSSION
Several recent papers have directly compared benzodiazepine use to propofol. The study by Carson et al (12) concluded that propofol resulted in fewer ventilator days when compared with intermittent lorazepam for patients ventilated Ͼ48 hrs. A subsequent model of the costs associated with use of propofol or intermittent lorazepam concluded that propofol has superior value (26) . Furthermore, a generic formulation of propofol became available after 1999, which may have contributed to its increasing appeal.
Our analysis has important implications for randomized clinical trials of sedative agents in the ICU. Recent trials of novel sedative agents such as dexmedetomidine used benzodiazepines as the control group (14, 15) . We show that infusions of benzodiazepines are uncommon compared with propofol infusions in the United States, and that the difference in prevalence is increasing over time. Selecting an appropriate control group for a clinical trial is complex, but is usually based on standard or usual practice, a concept that is difficult to define (27) . Based on our results, investigators in the United States should consider using propofol as the preferred control group given that most U.S. practitioners prefer propofol in a wide variety of settings.
Our analysis showed that several patient characteristics were associated with receiving IV infusion sedation if mechanically ventilated. Both older age and greater severity of illness were associated with a reduced likelihood of receiving IV infusion sedation. These findings may reflect concern of the medical team regarding hemodynamic instability and/or cognitive dysfunction associated with sedation in these sicker and older patients (28) . Having received cardiopulmonary resuscitation in the 24 hrs before admission to ICU was also associated with a decreased likelihood of IV infusion sedation, which supports the idea that sedation may often be withheld in the face of uncertainty regarding cognitive func- tion or hemodynamics. Alternatively, patients who are more severely ill may not manifest unwanted behavior, such as agitation, that may lead to the need for sedation. Women were also less likely to receive IV infusion sedation. A study by Arroliga and colleagues (25) of IV infusion sedation in mechanically ventilated patients also found that women, and older patients were less likely to receive IV infusion sedation, but did not find an association with severity of illness. We also found a higher hospital mortality for patients who received IV infusion benzodiazepines vs. propofol, despite similar mortality probability based on the MMP 0 -III model. This study was not designed to fully explore the causal relationship between IV infusion sedation choice and outcomes, which are best examined using physiological analyses and randomized controlled trials (29, 30) . Further data are needed to evaluate the criteria that clinicians use to select sedatives and to explore their effects on outcome.
Our study has several limitations. Most importantly, we were unable to analyze bolus sedation administration because accurate information on this route of delivery is not available in Project IM-PACT. Because midazolam, lorazepam, and narcotics, unlike propofol and dexmedetomidine, may be given as intermittent boluses, our study will underestimate the total benzodiazepine and narcotic use in mechanically ventilated patients. If we had only observed a shift over time from benzodiazepines to propofol, this may simply reflect a shift from IV infusion to intermittent benzodiazepine use. However, we observed an increase in overall IV infusion medication use reflected by an increase in both classes of medication. Therefore, we believe our major finding that IV infusion sedation use is increasing over time and is shifting to propofol is robust despite the lack of data on bolus medication.
While we had detailed data regarding medication use, we were unable to assess complex practices such as daily interruption of sedation, the use of sedation scores to target sedation level, and sedation weaning protocols (31) (32) (33) . Finally, this cohort study, like many others, is limited by the representativeness of the participating sites. Project IMPACT is a well described and studied group of ICUs that may be more focused on quality improvement than others. Still, this cohort included patients from many types of ICUs and hospitals, and many different regions in the country. The overall use of sedation, severity of illness, length of stay, and mortality are comparable to other studies (25, 34, 35) .
Armed with information on actual practice, more studies are now needed to assess outcomes associated with this practice, and to compare newer agents with appropriate controls. IV infusion sedation is an integral component of the care of sicker, mechanically ventilated intensive care patients, and is increasing in use. Propofol appears to be the current preferred medication for the majority of patients receiving IV infusion sedation in U.S. intensive care units, even among patients requiring prolonged mechanical ventilation.
